Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil P Shah

Showing results (21-30 of 119) with videos related to

Pageof 12
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemiaCatherine C Smith, Neil P Shah
Blood|April 16, 2025
How I individualize treatment for chronic-phase CMLAriel Monet Leyte-Vidal, Neil P Shah
Clinical Advances in Hematology & Oncology : H&O|March 14, 2015
Integrating current treatment options for TKI-resistant chronic myeloid leukemiaJerald P Radich, Neil P Shah, Michael J Mauro
Genes|October 28, 2023
Complex Genomic Rearrangements Involving <i>ETV6</i>::<i>ABL1</i> Gene Fusion in an Individual with Myeloid NeoplasmZhongxia Qi, Catherine Smith, Neil P Shah, et al.
Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine|July 28, 2012
Sonography of supraspinatus tendon abnormalities in the neutral versus Crass and modified Crass positions: a prospective studyNeil P Shah, Theodore T Miller, Harlan Stock, et al.
Bioorganic Chemistry|February 11, 2026
An unprecedented potent inhibitor of MV4-11 cells: investigations into the mechanism of action beyond FLT3 inhibitionXiuqi Wang, Rosa Anna DeFilippis, Huimin Geng, et al.
Journal of Medicinal Chemistry|June 5, 2024
Overcoming Secondary Mutations of Type II Kinase InhibitorsXiuqi Wang, Rosa Anna DeFilippis, Wei Yan, et al.
Blood|January 26, 2006
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosisNeil P Shah, Francis Y Lee, Roger Luo, et al.
Bioorganic Chemistry|November 23, 2023
N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutantsXiuqi Wang, Rosa Anna DeFilippis, Yuet-Kin Leung, et al.
European Journal of Medicinal Chemistry|March 14, 2015
Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitorsBrendan Frett, Nick McConnell, Catherine C Smith, et al.
Pageof 12

Showing results (21-30 of 119) with videos related to

Sort By:
Pageof 12
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemiaCatherine C Smith, Neil P Shah
Blood|April 16, 2025
How I individualize treatment for chronic-phase CMLAriel Monet Leyte-Vidal, Neil P Shah
Clinical Advances in Hematology & Oncology : H&O|March 14, 2015
Integrating current treatment options for TKI-resistant chronic myeloid leukemiaJerald P Radich, Neil P Shah, Michael J Mauro
Genes|October 28, 2023
Complex Genomic Rearrangements Involving <i>ETV6</i>::<i>ABL1</i> Gene Fusion in an Individual with Myeloid NeoplasmZhongxia Qi, Catherine Smith, Neil P Shah, et al.
Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine|July 28, 2012
Sonography of supraspinatus tendon abnormalities in the neutral versus Crass and modified Crass positions: a prospective studyNeil P Shah, Theodore T Miller, Harlan Stock, et al.
Bioorganic Chemistry|February 11, 2026
An unprecedented potent inhibitor of MV4-11 cells: investigations into the mechanism of action beyond FLT3 inhibitionXiuqi Wang, Rosa Anna DeFilippis, Huimin Geng, et al.
Journal of Medicinal Chemistry|June 5, 2024
Overcoming Secondary Mutations of Type II Kinase InhibitorsXiuqi Wang, Rosa Anna DeFilippis, Wei Yan, et al.
Blood|January 26, 2006
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosisNeil P Shah, Francis Y Lee, Roger Luo, et al.
Bioorganic Chemistry|November 23, 2023
N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutantsXiuqi Wang, Rosa Anna DeFilippis, Yuet-Kin Leung, et al.
European Journal of Medicinal Chemistry|March 14, 2015
Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitorsBrendan Frett, Nick McConnell, Catherine C Smith, et al.
Pageof 12